A review of life science current events reported by MedCity News this week:
J&J and Medtronic have contrasting acquisition strategies. Can both win? J&J’s strategy of growing through acquisitions appears to contrast with the acquisition strategy of another top-tier CEO, who like Gorsky, is charged with a turnaround: Medtronic (NYSE:MDT) CEO Omar Ishrak.
Why a Medtronic executive wants rival Edwards Lifesciences to succeed. “We need Edwards to succeed in transcatheter valve replacement,” Cornell told an audience gathered at the IBF MedTech Investing Conference in Minneapolis on Wednesday. “Success in a market floats all boats.”
5 cardiovascular disease medical device companies to watch. Here’s a look at five companies in the cardiology treatment and diagnostics space that you may be hearing more about in the years to come.
AstraZeneca, Takeda gout acquisitions make BCRX hopeful for gout drug deal. While the AstraZeneca and Takeda acquisitions likely remove those large pharmas from partnership contention, Stonehouse said the deals also shrink the market for other late-stage gout candidates and make the BioCryst compound more attractive and more valuable.
Covidien discloses $60M purchase of hypertension treatment firm.Covidien announced Tuesday that it will introduce a new renal denervation treatment at a European conference in mid May, but nowhere in the press release does the Massachusetts device firm name the developer of the technology: Maya Medical, based in Campbell, California.
By Deanna Pogorelc MedCity News
Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.More posts by Author
- Get Livefyre
- FAQ
